CER Daily Newsfeed

Value Viewpoint: June 13, 2025

(6/13, Kimberly Westrich, LinkedIn) comments “A new article published in Value in Health examines the effectiveness of AI and large language models in extracting data from cost-effectiveness analyses to support health economic research. The study evaluated the performance of a custom ChatGPT model (GPT), the Tufts CEA Registry Database (TCRD), and researcher-validated data (RVD), including 36 variables across 34 papers. Study authors found that the concordance rate between GPT and RVD was comparable to the concordance rate between TCRD and RVD. They also found that GPT outperformed TCRD in some variables but struggled with others.” Full

KRT Risk Lower With SGLT2 Inhibitor vs GLP-1 Receptor Agonist Use in Diabetic CKD

(6/13, Lauren Dembeck, PhD, Renal & Urology News) reports “The risk of progression to kidney replacement therapy (KRT) may be lower for patients taking sodium-glucose cotransporter 2 (SGLT2) inhibitors rather than glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and chronic kidney disease (CKD), a recent study suggests.” Full

Subcutaneous Tocilizumab Superior to Methotrexate in Chinese Patients With RA

(6/12, Hayden E. Klein, The American Journal of Managed Care) reports “Subcutaneous tocilizumab (Actemra; Genentech) used alone or in combination with methotrexate is significantly more effective than methotrexate monotherapy in treating moderate to severe rheumatoid arthritis (RA) among Chinese patients, according to findings from a large-scale randomized clinical trial published in JAMA Network Open.” Full

Explore Upcoming PCORI Funding Opportunities: What You Need To Know

(6/13, The PCORI Blog) comments “...Here’s an overview of PCORI funding opportunities open Aug. 12 to Sept. 23, 2025. Addressing Rare Diseases...Phased Large Awards for Comparative Effectiveness Research (PLACER)...Broad Pragmatic Studies (BPS)...Advancing the Science of Engagement in Research...” Full

Trump Administration Demands Pharma Companies Begin Drug Price Negotiations, a Day after Key Deadline

(6/12, Daniel Payne, STAT+) reports “...‘Under President Trump’s direction, HHS is demanding that pharmaceutical companies end their obstruction and come to the table—just as they already do with nearly every other economically comparable nation—to negotiate fair, transparent pricing for Americans,’ an agency spokesperson said in a statement to STAT, adding that the companies were ‘prevent[ing] progress of lowering prices for the American people.’” Subscription Required

Congress' "Doc Fix" Spurs Value-Based Care Concerns

(6/12, Maya Goldman, Axios) reports “...‘Signals matter in health care,’ said Shawn Martin, CEO of the American Academy of Family Physicians. ‘I think it's a signal [to physicians] of an entrenchment back in fee-for-service.’ The American College of Physicians, the trade group for internal medicine doctors, told lawmakers last month that it's concerned the policy as structured will disincentivize doctors' participation in value-based care. ‘It's being marketed as a long-term fix,’ said Mara McDermott, CEO of value-based care advocacy group Accountable for Health. ‘I don't read it that way. I read it as creating a new cliff.’” Full